Syngene International Establishes R&D Center for Amgen
The company established a dedicated research center in Bangalore, India for Amgen.
On September 6, 2016, Syngene International, a contract research organization based in Asia, announced that it has established a multi-disciplinary drug discovery and development center for Amgen in Bangalore, India. The center is named Syngene Amgen Research and Development Center (SARC) and is Syngene’s fourth exclusive R&D center. The company currently operates facilities for Bristol-Myers Squibb, Abbott Nutrition, and Baxter.
The center will be staffed by more than 100 Syngene scientists, working in close association with Amgen researchers. The center is customized to meet Amgen’s functional requirements and is configured to minimize solvent and effluent waste.
Syngene has partnered with Amgen in a variety of discovery and development projects. With the establishment of SARC, this association now extends into a multi-discipline collaboration, spanning capabilities in medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research, and pharmaceutical development.
Source: Syngene International
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
